medigraphic.com
ISSN 1995-9427 (Print)

2012, Number 2

<< Back Next >>

Invest Medicoquir 2012; 4 (2)

Utility immunoexpression of p53 and Ki-67 in patients with long-standing ulcerative colitis

Chao GL, Kim RI, de Armas FMC, Barroso ML, Tusen TY, Soto JA

Language: Spanish
References: 47
Page: 188-203
PDF size: 394.83 Kb.


ABSTRACT

Introduction. Patients with ulcerative colitis and longstanding pancolitis are at increased risk of developing colorectal cancer, which is a result of an inflammatory process that alters maintained and extensive tissue repair to cause failures and cellular DNA mutations, which are expressed as dysplasia histologically. The aim of this study was to determine the presence of dysplasia and identify the utility of p53 protein immunoexpression and Ki 67 in the surveillance of dysplasia in patients with ulcerative colitis and pancolitis, eight or more years of evolution. Methods. We performed a prospective descriptive study in 38 patients, 22 women (57,9%) and 16 men (42,1%), mean age 47,0±12,9 years, who underwent colonoscopy where evolutionary biopsy samples were taken at random for histological and immunohistochemical analysis. Results. It was observed that the degree of activity was detected 4 as many samples with dysplasia (n = 6) for 75% and showed that immunoexpression Ki67 and p53 was present in both degrees of severity of dysplasia. Conclusions. There was a high sensitivity and specificity for the detection of dysplasia in the samples studied.


REFERENCES

  1. Vergara F, Takahashi T, Gonzalez C. Conceptos actuales en colitis ulcerativa crónica inespecífica. Cir Gen. 2006;28:42-9.

  2. Salomon R. Enfermedad inflamatoria del intestino: colitis ulcerativa. Gac Med Caracas. 2007;115:183-202.

  3. Langan R, Gotsch P, Krafczyk M, Skillinge D. Ulcerative colitis: diagnosis and treatment. Am Fam Physician. 2007;76:1323-30.

  4. Lennard-Jones J. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170:2-6.

  5. Cabre E. Colitis ulcerosa: diagnóstico y diagnóstico diferencial. Gastroenterología y hepatología continuada. 2003;2:241-5.

  6. Leiper K, London I, Rhodes J. Managenent of the first presentation of severe acute colitis. Balliére Clin Gastroenterol. 1997;11:129-51.

  7. Derek P. Ulcerative colitis. In: Felman M, Friedman L, Sleisenger M, editor. Gastrointestinal and liver disease: pathophisiology, diagnosis, management. Philadelphia: WB Saunders 2002;p.2039-65.

  8. Modigliani R. Endoscopic management of inflamatory bowel disease. Am J Gastroenterol. 1994;89:553-65.

  9. Danese S, Fiocchi C. Ulcerative Colitis. N Engl J Med. 2011;365:1713-25.

  10. Kulaylat M, Dayton M. Ulcerative colitis and cancer. J Surg Oncol. 2010;101:706-712.

  11. Grupo de trabajo de la guía de práctica clínica de prevención del cáncer colorrectal. Actualización 2009. Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria, y Centro Cochrane Iberoamericano; 2009.

  12. Eaden J, Mayberry J. Guidelines for screening and surveillance of asymp-tomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51(Supl.5):10-2.

  13. Klementa I, Skalický P, Vyslouzil K, Starý L, Zboril P, Vomáckova K, et al. Risk of colorectal carcinoma in a patient with ulcerative colitis. Rozhl Chir. 2010;89:754-9.

  14. Eaden JA, Abrams K, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35.

  15. LlorFaré X. Cáncer y enfermedad inflamatoria intestinal. En: Gassul MA, Gomollón F. Hinojosa J, Obrador A, editores. Enfermedad inflamatoria intestinal. 3ra ed. Madrid: Aran 2007:p.475-80.

  16. Mortalidad. En: Zaca Peña E, editor. Anuario estadístico de salud 2010. La Habana: Dirección nacional de registros médicos y estadísticas de salud del Ministerio de Salud Pública; 2011:p.26-91. Zisman T, Rubin D. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008;14:2662–9.

  17. Díaz JL. Enfermedad Inflamatoria Intestinal (Parte 1). Revisiones en Medicina Interna Basada en la Evidencia; 2003.p.203-18. 18. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29:2727-37.

  18. Graziano A, Coraglio M, Masciangioli M, Gualdrini U, Gutiérrez A, Lumi C. Colitis ulcerosa y cáncer. Una asociación problemática. Rev Argent Cirug. 2008;95:111-9.

  19. Krok Karen L, Lichtenstein Gary R. Colorectal cancer in inflammatory bowel disease. Curr Opin Gastroenterol. 2004;20:43-8.

  20. Noffsinger A, Belli J, Miller M, Fenoglio-Preiser C. A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene. Histopathology.2001;39:482-92. 22. Breynaert C, Vermeire S, Rutgeerts P, Van Assche G. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk? Acta Gastroenterol Belg. 2008;71:367-72.

  21. Roa J, Roa E, Araya J, Villaseca M, Melo A, Burgos L. Gen supresor de tumores p53 en neoplasias digestivas. Rev Med Chile. 2000;128:1269-78.

  22. Shinozaki M, Watanabe T, Kubota Y. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis Colon Rectum. 2000;43(Suppl10):S34-9.

  23. Wong NA, Mayer NJ, Mackell S. Immunohistochemical assessment of Ki 67 and p 53 expressions assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology. 2000;37(2):108-14.

  24. Salas A. Evaluación de la displasia en las enfermedades digestivas. Gastroenterol Hepatol. 2007;30(10):602-11.

  25. Haber MM. Histologic precursors of gastrointestinal tract malignancy. Gastroenterol Clin North Am. 2002;31:395-419.

  26. Hirata I. The present status and problems with diagnosis and management of dysplasia/colitic cancer in ulcerative colitis. Clin J Gastroenterol. 2008;1:139-44.

  27. Ajioka Y, Watanabe H, Matsuda K. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study. Clin J Gastroenterol. 1995;30(Suppl 8):33-5.

  28. Ogata H. Diagnostic principles of colonoscopy in ulcerative colitis. Nippon Rinsho. 2005;63:787-93.

  29. Chao L. Presencia de displasia en pacientes con colitis ulcerosa de más de 10 años de evolución [tesis]. La Habana: InstitutoNacional de Gastroenterología; 2002.

  30. Connell WR, Sheffield JP, Kamm MA, Ritchie JK, Hawley PR, Lennard-Jones JE. Lower gastrointestinal malignancy in Crohn's disease. Gut. 1994;35:347.

  31. Contreras L. Rol de la histología en la enfermedad inflamatoria intestinal. Acta Gastroenterol Latinoam. 2007;18:218-20.

  32. Velayos F, Loftus E, Jess T, Harmsen W, Bida J, Zinsmeister A, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Clin J Gastroenterol. 2006;130:1941-9.

  33. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-9.

  34. Lukas M. Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis. 2010;28:619-24.

  35. Ullman T, Itzkowitz S. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807-16.

  36. Viennot S, Deleporte A, Moussata D, Nancey S, Flourié B, Reimund JM. Colon cancer in inflammatory bowel disease: recent trends, questions and answers. Gastroenterol Clin Biol. 2009;33(Suppl 3):190-201.

  37. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:553-71.

  38. Bernstein C. Ulcerative Colitis with low-grade dysplasia. Gastroenterology. 2004;127:950-956.

  39. Andersen SN, Rognum TO, Bakka A, Clausen OPF. Ki-67: a useful marker for the evaluation ofdysplasia in ulcerative colitis. J Clin Pathol. 1998;51:327–332.

  40. Radović S, Vukobrat Z, Selak I, Babić M. Abstract Expression of p53, bcl-2, and ki-67 Proteins in the Inflammatory Regenerative and Dysplastic Epithelial Lesions of Flat Colonic Mucosa. Bosnian Journal of Basic Medical Sciences. 2006;6:39-45.

  41. Mayurama K, Saigusa N, Bada S, Kino I. Inmunohistochemical distribution of p53 and Ki67 in 2 cases of colorectal carcinoma occurring in ulcerative colitis. GanTo Kagaku Ryoho. 1995;22(Suppl.2):145-8.

  42. Rosman-Urbach M, Niv Y, Birk Y, Smirnoff P, Zusman I, Morgenstern S, et al. A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients. Dis Colon Rectum. 2004;47:304-13.

  43. Heinzlmann M, Lang SM, Neynaber S, Reinshagen M, Emmrich J, Stratakis DF, et al. Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1061-6.

  44. Yoshizawa S, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, et al. Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis. 2007;13:865-73.

  45. Hussain SP. Inflammation and cancer: is AID aiding?. Gastroenterology. 2008;135:736-7.

  46. Mendoza-Rodríguez CA, Cerbón MA. Tumor suppressor gene p53: mechanisms of action in cell proliferation and death. Rev Invest Clin. 2001;53:266-73.

  47. Sobrino S, Trejo F, Hernández A, Herrera R, Sánchez, Alonso J. Endoscopia de magnificación para la detección de foco de cripta aberrante displásica en pacientes mexicanos con alto riesgo de cáncer de colon. Endoscopia. 2007;2:119-26.




2020     |     www.medigraphic.com